Dear Colleagues,

In vivo imaging encompasses a broad range of techniques and technologies that support the discovery and understanding of fundamental mechanisms of disease, disease pathologies and therapeutic efficacy of interventions, in both pre-clinical and clinical research. as well as in clinical practice. Magnetic Resonance Imaging (MRI), Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), Computed Tomography (CT) and, more recently, hybrid technologies, such as PET/CT and PET/MR, have transformed the capabilities of medical imaging and had a major impact on patient diagnosis and care.

Pre-clinical and clinical in vivo imaging provides scientists and clinicians with non-invasive visualisation of both biological structure and function/dysfunction and can be applied across a wide variety of disease states in oncology, neurology, cardiology and metabolic disease. Alongside the advances made in imaging technology, a particular strength across the spectrum of molecular imaging is the utilisation of highly specific probes and (radio)tracers that are able to target specific biochemical pathways, proteins, transporters and enzymes allowing for highly sensitive and selective visualisation of biological mechanisms.

Future advances in bioimaging will be contingent on the continued development of innovative chemical methodologies, whether through specific incorporation of isotopes, such as 13C and 15N, for dynamic nuclear hyperpolarisation (DNP) MR imaging, the radiolabelling of small molecules with 11C, 18F, the design of chelator chemistry for 157Gd, 68Ga, 89Zr, 99mTc, or the application bio-orthogonal chemical reactions. Advances in the chemistry of (radio)isotopes plays a crucial role in the expansion of the (radio)chemists’ toolbox and their ability to prepare evermore complex and specific molecular bioimaging markers to support the progression and increased capability of in vivo molecular imaging.

Dr. Edward G. Robins
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Molecular Imaging
• Bioimaging
• Magnetic Resonance Imaging (MRI)
• Positron Emission Tomography (PET)
• Fluorine-18
• Contrast Agent
• Radiotracer
• Radiopharmaceuticals